DESC:“AN IMPROVED PROCESS FOR PREPARATION OF BEMPEDOIC ACID”

FIELD OF THE INVENTION

The present invention relates to an improved process for the preparation of Bempedoic acid (I), comprising hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5), which is converting to Bempedoic acid (I).

BACKGROUND OF THE INVENTION

Bempedoic acid, chemical entitled 8-Hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid. Bempedoic acid is a small molecule inhibitor of adenosine triphosphate-citrate lyase (ACL), an enzyme upstream of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid is a prodrug that requires activation in liver to bempedoic acid-coenzyme A, which mediates competitive inhibition of ACL. Inhibition of ACL by bempedoic acid-coenzyme A decreases cholesterol synthesis in the liver leading to increased low-density lipoprotein receptor (LDLR) expression and LDL particle clearance from the blood. Therefore, inhibition of ACL by bempedoic acid-coenzyme A decreases low-density lipoprotein cholesterol (LDL-C) via the same pathway as HMG-CoA reductase inhibition by statins. An important differentiating feature of bempedoic acid is that, unlike statins, it does not inhibit cholesterol synthesis in skeletal muscle. The enzyme required to convert bempedoic acid to bempedoic acid-coenzyme A is not present in skeletal muscle. Therefore, bempedoic acid is not anticipated to mediate the adverse effects associated with inhibition of biological intermediates within the cholesterol biosynthesis pathway in skeletal muscle.

Bempedoic acid is a once-daily LDL-C lowering agent in phase 3 clinical trials. In phase 1 and 2 studies, bempedoic acid was efficacious in lowering LDL-C when used as monotherapy and when added to a statin and/or ezetimibe and was well tolerated in patients with statin intolerance. Its structural formula is as follows:

Bempedoic acid is reported in US 7335799 by Esperion Therapeutics Inc. The synthetic process for Bempedoic acid is reported in US ‘799, which comprises, compound of formula (I) is treated with ethyl isobutyrate in presence of Lithium diisopropylamide (LDA)/ tetrahydrofuran (THF) to obtain formula (2). The compound of formula (2) is treated with p-toluenesulfonyl methyl isocyanide in presence of tetra-n-butylammonium iodide (TBAI) / sodium hydride (NaH) / Dimethyl sulfoxide (DMSO) to obtain compound of formula (3). The compound of formula (3) is treated with hydrochloric acid/dichloromethane to obtain compound of formula (4). The compound of formula (4) is treated with potassium hydroxide (KOH) / ethanol (EtOH) to obtain compound of formula (5). The compound of formula (5) convert into Bempedoic acid (I) in presence of Sodium borohydride (NaBH4) / methanol (MeOH).

The above process is schematically shown as below:

IN 201941011853 of Dr. Reddy’s reported process for the preparation of Bempedoic acid (I), which comprises the compound of formula (4) is reduced in presence of NaBH4 /THF and water to obtain the compound of formula (6). The compound of formula (6) is hydrolysed in presence of EtOH / KOH / H2O / HCl, 10% EtOAc and hexanes to obtain Bempedoic acid (I).

The above process is schematically shown as below:

Scheme-I
The processes taught by prior art have several drawbacks namely not suitable for scale up at plant level, difficult, giving lower yields and less user friendly. Considering the drawbacks prior art process of Bempedoic acid, the present invention is simple, economical, financially cheaper plant friendly process, environment friendly process for the preparation of Bempedoic acid with better yields and purity.
There is always need for alternative preparative routes, which for example use reagents, solvents that are less expensive and/or easier to handle, consume smaller amounts of reagents and solvents provide a higher yield of product, have smaller and/or eco-friendly waste products and/or provide a product of higher purity.

Aforesaid reasons above there is a need to produce Bempedoic acid synthetically by industrially applicable method to ensure the availability with high purity. Hence, there is consequently a need development for new methods to sort out prior art existing methods. So, Further, there is a clear need to develop a method for the preparation of Bempedoic acid. The present invention is providing a simple, eco-friendly with high purity and good yield on industrial applicable process.

SUMMARY OF THE INVENTION

The present invention relates to an improved process for the preparation of Bempedoic acid (I).
In one aspect of the present invention, provides a process for the preparation of Bempedoic acid (I), comprising the steps of:

a) reacting the compound of formula (1) with isobutyronitrile in presence of base and solvent to obtain the compound of formula (2);

b) reacting the compound of formula (2) with p-toluenesulfonyl methyl isocyanide in presence of base and solvent to obtain compound of formula (3);

c) treating the compound of formula (3) with an acid to obtain compound of formula (4);

d) hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5); and

e) treating the compound of formula (5) with reducing agent in presence of solvent to obtain the Bempedoic acid (I).

In another aspect of the present invention, provides process for preparation of compound of formula (5) comprising hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to an improved process for the preparation of Bempedoic acid (I).
In one aspect of the present invention, provides an improved process for the preparation of Bempedoic acid (I), comprising the steps of:

a) reacting the compound of formula (1) with isobutyronitrile in presence of base and solvent to obtain the compound of formula (2);

b) reacting the compound of formula (2) with p-toluenesulfonyl methyl isocyanide in presence of base and solvent to obtain compound of formula (3);

c) treating the compound of formula (3) with an acid to obtain compound of formula (4);

d) hydrolyzing the compound of formula (4) with Ionic liquid to obtain the compound of formula (5); and

e) treating the compound of formula (5) with reducing agent in presence of solvent to obtain the Bempedoic acid (I).

The process according to the embodiment of the present invention, step a) involves the compound of formula (1) is reacted with isobutyronitrile in presence of base and solvent to obtain compound of formula (2). The reaction is carried out at room temperature for 10 to 12 hours. In a particular embodiment, the compound of the formula (1) is reacted with isobutyronitrile in the presence of diisopropylamine/THF or n-butyllithium/hexane at room temperature to obtain a compound of formula (2).

The process according to the embodiment of the present invention, step b) involves the compound of formula (2) is reacted with p-toluenesulfonyl methyl isocyanide in presence of base and solvent to obtain compound of formula (3). The reaction is carried out temperature at 0°C for 2 to 4 hours. In a particular embodiment, the compound of the formula (2) is reacted with p-toluenesulfonyl methyl isocyanide in presence of sodium hydride and dimethylformamide at 0oC to obtain a compound of formula (3).

The process according to the embodiment of the present invention, step c) involves the compound of formula (3) is treated with acid in presence of solvent to obtain compound of formula (4). The reaction is carried out temperature at 0°C for 2 to 4 hours. In a particular embodiment, the compound of the formula (3) is treated with hydrochloric acid in presence of Methyl tert-butyl ether (MTBE) at 0°C to obtain a compound of formula (4).

The process according to the embodiment of the present invention, step d) involves the compound of formula (4) is treated with ionic liquid in presence of solvent to obtain compound of formula (5). The reaction is carried out temperature at 100°C to 110°C for 4-5 hours. In a particular embodiment, the compound of the formula (4) is treated with 1-butyl-3-methylimidazolium hydrogen sulphate (BMIM.HSO4) at 100°C-110°C to obtain a compound of formula (5).

The process according to the embodiment of the present invention, step e) involves the compound of formula (5) is treated with reducing agent in presence of solvent to obtain compound of formula (I). The reaction is carried out at room temperature for 2-4 hours. In a particular embodiment, the compound of the formula (5) is treated with sodium borohydride in presence of methanol at room temperature to obtain a compound of formula (I).

In another aspect of the present invention provides process for preparation of compound of formula (5) comprising hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5)

The process according to the embodiment of the present invention, involves the compound of formula (4) is treated with ionic liquid in presence of solvent to obtain compound of formula (5). The reaction is carried out temperature at 100°C to 110°C for 4-5 hours. In a particular embodiment, the compound of the formula (4) is treated with 1-butyl-3-methylimidazolium hydrogen sulphate (BMIM HSO4) at 100°C-110°C to obtain a compound of formula (5).

According to an embodiment of the present invention, wherein the solvent selected from “hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, pet ether, benzene, toluene, pentane, cycloheptane, methyl cyclohexane, ethylbenzene, m-, o, or p xylene, or naphthalene and the like; “ether solvents” such as dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, 1,2-dimethoxy ethane and the like; “ester solvents” such as methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate and the like; “polar-aprotic solvents such as dimethylacetamide (DMA), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and the like; “chloro solvents” such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; “ketone solvents” such as acetone, methyl ethyl ketone, methyl isobutylketone and the like; “nitrile solvents” such as acetonitrile, propionitrile, isobutyronitrile and the like; “alcohol solvents” such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene glycol), 2-methoxyethanol, l, 2-ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol and the like; “polar solvents” such as water or mixtures thereof.

According to an embodiment of the present invention, wherein the base is selected from inorganic bases like “alkali metal hydroxides” such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; “alkali metal carbonates” such as sodium carbonate, potassium carbonate, lithium carbonate, and the like; “alkali metal bicarbonates” such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate and the like; “alkali metal hydrides” such as sodium hydride, potassium hydride, lithium hydride and the like; ammonia and organic bases such as “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide and the like; triethyl amine, methyl amine, ethylamine, 1,8-diaza bicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo(4.3.0)non-5-ene (DBN), lithiumdiisopropylamide (LDA), n-butyl lithium, tribenzylamine, isopropylamine, diisopropylamine, diisopropylethylamine, N-methyl morpholine, N-ethylmorpholine, piperidine, dimethylaminopyridine, morpholine, pyridine, 2,6-lutidine, 2,4,6-collidine, imidazole, 1-methyl imidazole, 1,2,4-triazole, 1,4-diazabicyclo [2.2.2]octane (DABCO) or mixtures thereof.;

According to an embodiment of the present invention, wherein the Ionic liquid is selected from imidazole and 1-methylimidazole, 1,3-dimethylimidazolium, 1-ethyl-3-methylimidazolium [EMIM], 1-hexyl-3-methylimidazolium [HxMIM], 1-butyl-3-methylimidazolium (BMIM), 1-butyl-3-methylimidazolium hydrogen sulphate ([BMIM] HSO4), 1-butyl-2,3-dimethylimidazolium [bdmim], 1-n butyl 3-methylimidazolium hydroxide [BMIM] [OH], 1-butyl 3-methyl imidazolium tetrafluoroborate [BMIm][BF4], 1-butyl-3- methylimidazolium hexafluorophosphate [BMIM][PF6], 1-butyl-3-methylimidazoliumchloride [bmim][Cl], 1-Octylpyridinium bis(trifluoromethanesulfonyl)imide [C8pyr][NTf2]
1-Octylpyridinium tetrafluoroborate [C8pyr][BF4], 1-Octyl-1-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide [C8C1pyr][NTf2], 1-Octyl-1-methyl morpholinium dicyanamide [C8C1mor][N(CN)2], 1-Octyl-3-methylimidazolium tetrafluoroborate [C8C1im][BF4], 1-Octyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide [C8C1im][NTf2], 1-Octyl-4-methylpyridinium bis(trifluoromethanesulfonyl)imide [C8C14pyr][NTf2], 1-Octylpyridinium bis(trifluoromethanesulfonyl)imide [C8C13pyr][NTf2], 1-Octyl-3-methylpyridinium tetrafluoroborate [C8C13pyr][BF4],1-Octyl-3-methylpyridinium bis(trifluoromethanesulfonyl)imide [C8C13pyr][NTf2], 1-Octyl-2-methylpyridinium bis(trifluoromethanesulfonyl)imide [C8C12pyr][NTf2], 1-Heptyl-1-methylmorpholinium dicyanamide [C7C1mor][N(CN)2], 1-Hexylpyridinium bis(trifluoromethanesulfonyl)imide [C6pyr][NTf2], 1-Hexyl-1-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide [C6C1pyrr][NTf2], 1-Hexyl-1-methylmorpholinium dicyanamide [C6C1mor][N(CN)2],1-Hexyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide [C6C1im][NTf2],1-Hexyl-3-methylimidazolium chloride [C6C1im]Cl,1-Hexyl-3-methylimidazolium bromide [C6C1im]Br, 1-Pentyl-1-methylmorpholinium dicyanamide [C5C1mor][N(CN)2], 1-Pentyl-1-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide[C5C1pyrr][NTf2], 1-Pentyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide [C5C1im][NTf2], 1-Butylpyridinium bis(trifluoromethanesulfonyl)imide [C4pyr][NTf2], 1-Butylpyridinium tetrafluoroborate [C4pyr][BF4], 1-Butyl-1-methylmorpholinium dicyanamide [C4C1mor][N(CN)2], 1-Butyl-1-methylpiperidinium dicyanamide [C4C1pip][N(CN)2], 1-Butyl-1-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide [C4C1pyrr][NTf2], 1-Butyl-3-methylimidazolium tetrafluoroborate [C4C1im][BF4], 1-Butyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide [C4C1im][NTf2],
1-Butyl-3-methylimidazolium octanesulfonate [C4C1im][(C8)OSO3],
1-Butyl-3-methylimidazolium hexafluorophosphate [C4C1im][PF6],
1-Butyl-3-methylimidazolium hexafluoroantimonate [C4C1im][SbF6],
1-Butyl-3-methylimidazolium trifluoromethanesulfonate [C4C1im][OTf],
1-Butyl-3-methylimidazolium acetate [C4C1im][MeCO2], 1-Butyl-3-methylimidazolium dicyanamide [C4C1im][N(CN)2],1-Butyl-3-methylimidazolium methylsulfate [C4C1im][MeSO4],
1-Butyl-3-methylimidazolium butyrate [C4C1im][PrCO2], 1-Butyl-3-methylimidazolium glycolate [C4C1im][(HO)C1CO2], 1-Butyl-3-methylimidazolium propionate [C4C1im][EtCO2], 1-Butyl-3-methylimidazolium dimethylphosphate [C4C1im][Me2PO4], 1-Butyl-3-methylimidazolium methanesulfonate [C4C1im][MeSO3], 1-Butyl-3-methylimidazolium malate [C4C1im][O2CCH2CH(OH)CO2], 1-Butyl-3-methylimidazolium succinate [C4C1im][O2CCH2CH2CO2], 1-Butyl-3-methylimidazolium maleate [C4C1im][O2CCHCHCO2], 1-Butyl-2,3-dimethylimidazolium tetrafluoroborate [C4C1C1im][BF4], 1-Butyl-2,3-dimethylimidazoliumbis (trifluoromethanesulfonyl) imide [C4C1C1im][NTf2],1-Butyl-1-methylpyrrolidinium dimethylphosphate [C4C1pyrr][Me2PO4], 1-(2-Ethoxyethyl)-1-methylpyrrolidinium bis(trifluoromethanesulfonyl)imide [(C2OC2)C1pyrr][NTf2], 1-Propyl-1-methylmorpholinium dicyanamide [C3C1mor][N(CN)2], 1-Ethyl-1-methylmorpholinium dicyanamide [C2C1mor][N(CN)2],1-Ethyl-1-methylmorpholinium bis(trifluoromethanesulfonyl)imide [C2C1mor][N(CN)2], 1-Ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide [C2C1im][NTf2],
1-Ethyl-3-methylimidazolium hexanesulfonate [C2C1im][(C6)SO4], 1-Ethyl-3-methylimidazolium octanesulfonate [C2C1im][(C8)SO4], 1-Ethyl-3-methylimidazolium acetate [C2C1im][MeCO2], 4-(1-methylimidazolium-3-yl)-1-
butane sulfonate (Zbsmim) and 4-(1-imidazolium-1-yl)-1-butane
sulfonate (ZbsHim)
According to an embodiment of the present invention, wherein the reducing agent are selected from iron powder, sodium borohydride (NaBH4), nickel, raney nickel, rhodium, palladium hydroxide (Pd(OH)2), palladium acetate, lithium aluminum hydride, stannic chloride, diisobutylaluminum hydride and diborane sodium amalgam, lithium borohydride, sodium aluminium hydride, hydrazine hydrate, sodium dithionate, sodium sulfide, ammonium sulfide, palladium catalyst (e.9,, palladium carbon, palladium hydroxide carbon, palladium oxide and the like), nickel catalyst (e.9., Raney-nickel and the like), platinum catalyst (e.9., platinum oxide, platinum carbon and the like), Rhodium catalyst (e,g., rhodium carbon and the like), cobalt catalyst (e.9,, Raney-cobalt and the like) and the like.

According to an embodiment of the present invention, wherein the acid is selected from hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, alkyl/aryl sulfonic acids such as methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.

The above overall process is schematically shown as below:

The advantages of the present invention as follows:
? Single pot processing Step-d to Bempedoic acid without isolation of intermediate, which is an extremely flexible technology.
? Using Ionic liquid the reaction was completed in less period of time. Hence, this process is commercially feasible process.
? Particularly [BMIM] HSO4 Ionic liquid the reaction was completed in less period of time (4h); Hence, this process is commercially feasible process.
? The present invention improved with respect to quality and yield by involving [BMIM] HSO4. The present invention provides the 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid with high purity and good yield.

? The advantage of the present invention is high yield and purity on eco-friendly, commercially viable and industrial applicable process.
The process details of the invention are provided in the examples given below, which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.

EXAMPLES

Example-1: Preparation of 7-Chloro-2,2-dimethylheptanenitrile:

Diisopropylamine (65.5 g, 0.648 mol) was dissolved in tetrahydrofuran (500 mL) and allowed to cool at -20oC to -30oC, followed by dropwise addition of n-BuLi (2.5 M) in n-Hexane for 30 min. The reaction mixture allowed to cool at -70 oC to -78 oC, followed by addition of isobutyronitrile (44.75 g, 0.64 mol) and stir for 30 mins. The obtained reaction mixture was slowly added to 1-bromo-5-chloro pentane (100 g, 0.54 mol) in tetrahydrofuran (1000 mL) and stir for 12h. After completion of the reaction, the reaction mixture was quenched with 1N hydrochloric acid (100 mL), then the reaction mass temperature slowly raised at room temperature (25-30 oC) and extracted with ethyl acetate (500 mLx2). The combined organic extracts were washed with water (100 mL) and brine solution (50 mL). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to obtain 7-Chloro-2,2-dimethylheptanenitrile.
Yield: 80 g. (85%)
Purity: 88%
Example-2: Preparation of 8-isocyano-2,2,14,14-tetramethyl-8-tosylpentadecanedinitrile:
7-Chloro-2,2-dimethylheptanenitrile (80 g, 0.461 mol), dimethylformamide (200 mL) and TOSMIC (40.5g, 0.209 mol) were added in RB flask. The obtained reaction was allowed to cool at 0oC, followed by added portion wise sodium hydride (50% in paraffin, 18.5 g, 0.461 mol) and stir for 4 hours at 0oC. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride and slowly brought to room temperature (25-30oC). The reaction was diluted with water and extracted with EtOAc. The combined extracts were washed with brine, dried over sodium sulphate and concentrated. Isopropyl alcohol was added to the crude reaction mass and stir at 0oC to give a light brown solid. The solid was filtered and washed with ice cold IPA to obtain 8-Isocyano-2,2,14,14-tetramethyl-8-tosylpentadecanedinitrile.
Yield: 46 g.
Purity: 95%
Example-3: Preparation of 2,2,14,14-tetramethyl-8-oxopentadecanedinitrile:
8-Isocyano-2,2,14,14-tetramethyl-8-tosylpentadecanedinitrile (40g, 0.085 mol) and MTBE (20 mL) was added in to RB flask. The reaction mixture was cooled to 0oC and added 5N hydrochloric acid (20 mL), stir for 4h at 0oC. After completion of the reaction, the reaction mixture was quenched with saturated sodium bicarbonate solution (100 mL) and extracted with ethyl acetate. The combined extracts were washed with water and brine solution. The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to obtain 2,2,14,14-Tetramethyl-8-oxopentadecanedinitrile as sticky liquid which solidifies as an off-white solid.
Yield: 22 g. (83%)
Purity: 96%
Example-4: Preparation of 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid:
2,2,14,14-Tetramethyl-8-oxopentadecanedinitrile (4 mg, 1.64 mmol) was dissolved in 1-butyl-3-methylimidazolium hydrogen sulphate ([BMIM] (HSO4) (5 mL) and allowed to stir for 4h at 100oC – 110oC. After completion of the reaction, the reaction was concentrated under reduced pressure. The reaction mass was diluted with water and extracted with EtOAc. The combined extracts were washed with water and brine solution, dried over sodium sulphate and concentrated. The crude optionally converted without further purification to the next step.
Yield: 534 mg. (95%)
Example-5: Preparation of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid:
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid (500 mg, 1.46 mmol) was dissolved in methanol (10 mL) and allow to cool at 0 oC, followed by portion wise addition of sodium borohydride (532 mg, 2.9 mmol). The reaction temperature raised to room temperature and stir for 4h. After completion of the reaction, the reaction mixture was concentrated. The reaction mixture was cooled at 0oC, adjusted pH with 1N hydrochloric acid and extracted with ethyl acetate. The combined extracts were dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude reaction mixture was further purified to obtain 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as an off-white solid.
Yield: 452 mg. (90%)
Purity: 99.5%

,CLAIMS:1. An improved process for the preparation of Bempedoic acid (I), comprising the steps of:
a) reacting the compound of formula (1) with isobutyronitrile in presence of base and solvent to obtain the compound of formula (2);

b) reacting the compound of formula (2) with p-toluenesulfonyl methyl isocyanide in presence of base and solvent to obtain compound of formula (3);

c) treating the compound of formula (3) with an acid to obtain compound of formula (4);

d) hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5);

e) treating the compound of formula (5) with reducing agent in presence of solvent to obtain Bempedoic acid (I).

2. The process as claimed in claim 1, wherein the base selected from sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, sodium hydride, potassium hydride, lithium hydride, lithiumdiisopropylamide (LDA), n-butyl lithium, tribenzylamine, isopropylamine, diisopropylamine, diisopropylethylamine.
3. The process as claimed in claim 1, wherein the acid selected from hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid.
4. The process as claimed in claim 1, wherein the ionic liquid selected from imidazole, 1-methylimidazole, 1,3-dimethylimidazolium, 1-ethyl-3-methylimidazolium [EMIM], 1-hexyl-3-methylimidazolium [HxMIM], 1-butyl-3-methylimidazolium (BMIM), 1-butyl-3-methylimidazolium hydrogen sulphate ([BMIM] (HSO4), 1-butyl-2,3-dimethylimidazolium [bdmim], 1-n butyl 3-methylimidazolium hydroxide [BMIM] [OH], 1-butyl 3-methyl imidazolium tetrafluoroborate [BMIm][BF4], 1-butyl-3-methylimidazolium hexafluorophosphate [BMIM][PF6], 1-butyl-3-methylimidazoliumchloride [bmim][Cl].
5. The process as claimed in claim 1, wherein the reducing agent selected from iron powder, sodium borohydride (NaBH4), nickel, raney nickel, rhodium, palladium hydroxide (Pd(OH)2), palladium acetate, lithium aluminum hydride, stannic chloride, diisobutylaluminum hydride and diborane sodium amalgam, lithium borohydride, sodium aluminium hydride, hydrazine hydrate, sodium dithionate, sodium sulfide, ammonium sulfide, palladium carbon, palladium hydroxide carbon, palladium oxide, Raney-nickel, platinum oxide, platinum carbon, rhodium carbon, Raney-cobalt.
6. The process as claimed in claim 1, wherein the solvent selected from n-hexane, n-heptane, cyclohexane, pet ether, benzene, toluene, pentane, cycloheptane, methyl cyclohexane, ethylbenzene, m-, o-, p-xylene, naphthalene, dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, 1,2-dimethoxy ethane, methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate, dimethylacetamide (DMA), dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP), dichloromethane, dichloroethane, chloroform, carbon tetrachloride, acetone, methyl ethyl ketone, methyl isobutylketone, acetonitrile, propionitrile, isobutyronitrile, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene glycol), 2-methoxyethanol, l,2-ethoxyethanol, diethylene glycol, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, glycerol, water or mixtures thereof.
7. A process for the preparation of compound of formula (5), comprising hydrolyzing the compound of formula (4) with ionic liquid to obtain the compound of formula (5).

8. The process as claimed in claim 7, wherein the ionic liquid selected from imidazole, 1-methylimidazole, 1,3-dimethylimidazolium, 1-ethyl-3-methylimidazolium [EMIM], 1-hexyl-3-methylimidazolium [HxMIM], 1-butyl-3-methylimidazolium (BMIM), 1-butyl-3-methylimidazolium hydrogen sulphate ([BMIM] (HSO4), 1-butyl-2,3-dimethylimidazolium [bdmim], 1-n butyl 3-methylimidazolium hydroxide [BMIM] [OH], 1-butyl 3-methyl imidazolium tetrafluoroborate [BMIm][BF4], 1-butyl-3-methylimidazolium hexafluorophosphate [BMIM][PF6], 1-butyl-3-methylimidazoliumchloride [bmim][Cl].